ALZN NASDAQ
Atlanta, GA 30326
US
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AULT MILTON C III | P-Purchase | 108,388 | $1.00 | 2026-04-14 |
| AULT MILTON C III | S-Sale | 1,851 | $2.07 | 2025-12-23 |
| Horne William B. | S-Sale | 3,333 | $2.12 | 2025-12-19 |
| McGrath Lynne Fahey | S-Sale | 30 | $2.29 | 2025-10-23 |
| AULT MILTON C III | S-Sale | 20,397 | $2.32 | 2025-10-09 |